Clinical Trials Logo

Clinical Trial Summary

Phase I dose escalating trial. Primary objectives of this study are to assess the safety and tolerability of Simmiparib following single and multiple oral doses in patients with advanced solid malignancies, to determine the maximum tolerance dose (MTD) and dose limiting toxicity (DLT), and pharmacokinetic profile.

The Secondary objective is to observe the preliminary antitumor effect of Simmiparib.


Clinical Trial Description

This single-center, nonrandomized, open-label, dose-escalating study. The trial was divided into dose escalation and expansion stages. ;


Study Design

Intervention Model: Single Group Assignment, Masking: Open Label


Related Conditions & MeSH terms


NCT number NCT02993913
Study type Interventional
Source Shanghai Acebright Pharmaceuticals Co., Ltd.
Contact MohammadAbdul Kaium
Phone 0086-21-51323300
Email [email protected]
Status Recruiting
Phase Phase 1
Start date December 2016